Side-by-side · Research reference

AHK-CuvsGHRP-6

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BPhase 1HUMAN-REVIEWED10/36 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

AHK-Cu

GHRP-6

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Ghrelin receptor (GHS-R1a)Bowers 1990

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Feedback intact?

—

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

AHK-Cu

GHRP-6

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

1–3× per day

Route

Topical — scalp or dermal application

—

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

Phase 1 + clinical practiceBowers 1990

Duration

Not established — cosmetic protocols typically 8–12 weeks

8–12 weeks on / 4 off

Standard dose

—

100–200 mcg per injectionBowers 1990

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-meal preferred for appetite support

Half-life

—

~15 minMalagón 1999

04Side Effects & Safety

Parameter

AHK-Cu

GHRP-6

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Hunger

—

Pronounced — defining feature vs ipamorelin

Cortisol elevation

—

Mild

Prolactin elevation

—

Mild

Injection site reaction

—

Mild

Cancer risk

—

Contraindicated in active malignancy

Pregnancy / OB

—

Avoid

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

05Administration Protocol

Parameter

AHK-Cu

GHRP-6

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

SQ — abdomen. Rotate sites.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Pre-meal for appetite support; pre-sleep for GH alignment.

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

GHRP-6

— no documented stacks